Education
About Us
Working with TipRanks
Follow Us
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
CAMP Stock Chart & Stats
$5.00
-$0.13(-2.84%)
At close: 4:00 PM EST
$5.00
-$0.13(-2.84%)
Day’s Range― - ―
52-Week Range$1.31 - $7.75
Previous Close$4.45
Volume38.22K
Average Volume (3M)1.59M
Market Cap
$259.60M
Enterprise Value-$1.34M
Total Cash (Recent Filing)$109.52M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta1.87
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,919,320
10 Day Avg. Volume141,089
30 Day Avg. Volume1,592,597
Financial Highlights & Ratios
PEG Ratio6.16
Price to Book (P/B)3.90
Price to Sales (P/S)53.24
P/FCF Ratio-6.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.38
Enterprise Value/Gross Profit-0.50
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$7.92Price Target Upside58.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Expansion FundingProceeds from the recent capital raise enable expansion of the planned early-stage study for the lead program into additional regions, addition of secondary outcome measures, and funding for an open-label extension.
Strategic Partnership ValidationStrategic collaboration with a major pharmaceutical company validates the regulatory RNA-targeting platform and includes an upfront payment that materially strengthens the company's balance sheet.
Therapeutic Differentiation And TolerabilityLead candidate CMP-002 targets restoration of SYNGAP1 expression and has shown clinical tolerability to date, supporting its potential as a disease-modifying therapy across multiple symptoms.
Bears Say
Clinical Execution UncertaintyKey elements of the clinical plan, including study design and the target patient population, remain to be finalized, creating uncertainty around execution and trial timing.
Partnership Strategy ShiftManagement's emphasis on prioritizing internal pipeline projects may limit pursuit of multiple external partnerships and reduce near-term collaboration opportunities.
Resource-driven Collaboration ConstraintsLimited internal resources could constrain the number of new collaborations the company can sign, despite capacity existing for additional partnerships.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $7.75 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $259.60M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
Currently, no data Available
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 51,919,320 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CAMP4 Therapeutics Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.92 (58.40% Upside)
$7.92 (58.40% Upside)
Blogger Sentiment
Bullish
CAMP Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.71%
12-Months-Change
Fundamentals
Return on Equity
-162.49%
Trailing 12-Months
Asset Growth
50.44%
Trailing 12-Months
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CAMP Stock 12 Month Forecast
Average Price Target
$7.92
▲(58.40% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
28.09% Insiders
4.72% Mutual Funds
41.76% Other Institutional Investors
22.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---